Shares fall after trial fail for Juniper Pharmaceuticals
Shares of Boston-based women ’s health biotech Juniper Pharmaceuticals sank after the company announced that a gel hoped to reduce pain in women during an endometrial biopsy failed a mid-stage trial.
The news sent shares of the company down 24 percent to $5.38 — its lowest point in more than a year — as of 11:30 a.m.
Ju niper’s (Nasdaq: JNP) Phase 2b clinical trial tested its 10 percent lidocaine bioadhesive vaginal gel, COL-1077, for the reduction of pain intensity. But Juniper said late…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Don Seiffert Source Type: news
More News: Aci-Jel | Biotechnology | Clinical Trials | Endometrial Biopsy | Health | Health Management | Juniper | Lidoderm | Pain | Pharmaceuticals | Women